A rising rookie with strong potential!

March 31, 2022/eMedClub News/--IN8bio (NASDAQ: INAB), which focuses on γδ T cell therapy, recently presented at the 48th annual meeting of the European Society for Blood and Marrow Transplantation (EBMT).
A clinical update from the ongoing Phase 1 trial of INB-100 is presented here
.

INB-100 is an allogeneic γδ T cell therapy candidate for leukemia patients who have undergone haploidentical hematopoietic stem cell transplantation (HSCT)
.

To date, 3 patients with high-risk or relapsed acute myeloid leukemia (AML) with complex cytogenetics have been treated
.

Two of these patients have been in remission for nearly two years, and the third patient has sustained remission nine months after treatment
.

Exploratory clinical data also showed that treated patients showed immune system reconstitution, with positive trends in immune cell levels, including αβ T cells, B cells, and γδ T cells, implying that the systemic immune system may show a positive long-term response
.

Toxicity profiles continued to be manageable, with no grade 3 or higher treatment-related adverse events
.

IN8bio is a clinical-stage biopharmaceutical company aiming to develop novel immunotherapies for cancer using allogeneic and autologous genetically modified γδ T cells
.

At present, in addition to INB-100, the company's R&D pipeline includes 3 other projects: INB-200, the fastest-growing genetically modified autologous gamma-delta T cell candidate, which is currently undergoing Phase 1 trials in glioblastoma and solid tumor preclinical studies of combination therapy; and preclinical programs INB-400 and CAR-γδ T product candidate INB-300
.

▲ The company’s pipeline (Image source: IN8bio) γδ T cells: A promising up-and-coming γδ T cell has the characteristics of the innate and adaptive immune systems, and can act as a functional bridge between these two key systems to affect tumor killing
.

Thus, γδ T cells are not only capable of being activated to kill tumor cells immediately and efficiently, but they also have the potential to promote cascades that trigger innate and adaptive immune cells through cytokine release and antigen presentation, generate immune memory, induce Potent and durable antitumor response
.

More importantly, γδ T cells recognize antigens independently of MHC, thereby reducing the risk of allogeneic reactions and graft-versus-host disease, and are a suitable source of "off-the-shelf" cell products
.

In addition, γδ T cells have good tissue infiltration ability and can survive and function in the tumor microenvironment
.

Currently, a number of international companies are developing immunotherapy based on γδ T cells, including Adicet, LAVA Therapeutics (listed), GammaDelta (acquired by Takeda), IN8bio (listed), TC Biopharm (listed), Gadeta, ImCheck, Gimv, Juno, CytoMed, Acopedia,
etc.

In July 2021, a Phase 1/2a clinical trial of LAVA Therapeutics' lead product LAVA-051 in patients with relapsed and/or refractory hematological tumors has completed the first patient dosing
.

The drug will activate γδ T cells and type 1 natural killer T (NKT) cells to specifically kill CD1d-expressing blood tumors
.

LAVA-051 is a "first-in-class" humanized bispecific γδ T cell binding antibody (γδ bsTCE) designed to activate γδ T cells and type 1 natural killer T (NKT) cells, expressing a specific killer Hematological neoplasms of CD1d
.

▲ γδ bsTCE (Image source: LAVA official website) Recommended reading: Bispecific γδ T cell binding antibody is here! Possessing multiple anti-tumor functionsYimai Meng broke the news In October 2021, Takeda Pharmaceutical Co.
, Ltd.
announced the completion of the acquisition of GammaDelta Therapeutics, an immunotherapy company.
Through this acquisition, Takeda will obtain GammaDelta's allogeneic variable δ1 (Vδ1).
γδ T cell therapy platforms, including blood-derived and tissue-derived platforms, and early-stage cell therapy programs
.

Recommended reading: Takeda acquires natural killer γδ T cells and is committed to creating the next generation of "spot" CAR-T innovative productsYimai Meng broke the news In December 2021, Adicet announced its allogeneic CAR-γδ T cells targeting CD20 The therapy ADI-001 in B-cell non-Hodgkin's lymphoma received positive interim data in a dose-escalation Phase 1 clinical trial
.

Among the four evaluable patients, 1 patient in the high-dose group and 1 patient in the low-dose group achieved a complete remission (CR), and the other two patients in the low-dose group achieved a partial remission (PR)
.

▲ ADI-001 interim data summary (image source: Adicet official website) Recommended reading: "Spot" CAR-γδ T therapy announced the latest clinical data: up to 75% remission rate! Yimai Meng broke the news that in March this year, TC Biopharm announced the positive interim results of the Phase 1a/2b clinical study of its main product OmnImmune® (TCB-002) in the treatment of relapsed/refractory acute myeloid leukemia (AML); and Received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) and the Research Ethics Committee to initiate a Phase 2b/3 clinical trial
.

At the same time, the US FDA also granted OmnImmune orphan drug designation for the treatment of AML
.

TC Biopharm successfully landed on Nasdaq in February this year
.

Recommended reading: Good news spreads frequently! Allogeneic γδ T cell therapy starts phase 2b/3 clinical trialYimai Meng broke the news Reference: 1.
https://in8bio.
com/pipeline/2.
https:// in8bio-presents-clinical-update-from-the-ongoing-phase-1-trial-of-inb-100-an-allogeneic-gamma-delta-t-cell-therapy-in-leukemia-patients-undergoing-hematopoietic- stem-cell-transplant/——List of recent popular activities——▼On March 31, authoritative interpretation of the characterization analysis technology of AAV gene therapy drugs▼On March 31, Guangzhou, the theme salon of quality control challenge of virus delivery vector AAV▼7 1st-3rd, Shanghai, 2022 Shanghai International Bio-Innovative Drug Industry Expo